Drug intelligence / Profile preview

triptorelin + progesterone

Development stage
Unknown
Lead developer
Assiut University
Modality
Peptides, Small Molecules
Administration
Subcutaneous, Vaginal
01

Overview

This combination therapy consists of the gonadotropin-releasing hormone (GnRH) agonist triptorelin and the steroid hormone progesterone, utilized as luteal phase support (LPS) in assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Triptorelin acts as an agonist at the GnRH receptor in the pituitary gland, inducing a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that stimulates the corpora lutea to enhance endogenous steroid synthesis. Progesterone provides direct exogenous hormonal support to the endometrium, facilitating embryo implantation and maintaining early pregnancy. This specific investigational protocol typically involves a single mid-luteal dose of triptorelin (0.1 mg) administered subcutaneously on day 6 after oocyte pickup, in addition to standard transvaginal progesterone supplementation.

Other names
gonadotropins releasing hormone agonist + progesteroneGnRHa + progesteronetriptorelin and progesterone
02

Targets

PR (Progesterone receptor)GR (Glucocorticoid receptor)AR (Adrenergic receptors)GnRHR (Gonadotropin-releasing hormone receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on triptorelin + progesterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on triptorelin + progesterone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call